<DOC>
	<DOCNO>NCT03075878</DOCNO>
	<brief_summary>This study conduct evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , immunogenicity , effect warm autoimmune hemolytic anemia ( WAIHA ) disease activity marker intravenous ( IV ) SYNT001 .</brief_summary>
	<brief_title>A Safety Study SYNT001 Subjects With Chronic , Stable Warm Autoimmune Hemolytic Anemia ( WAIHA )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<criteria>Subjects must meet follow criterion include : Willing able read , understand sign inform consent form Confirmed diagnosis enrol physician WAIHA Must use medically acceptable contraception Subjects meet follow criterion exclude : Subject unable unwilling comply protocol Active nonhematologic malignancy history nonhematologic malignancy 3 year prior screen ( exclusive nonmelanoma skin cancer cervical cancer situ ) Positive HIV hepatitis C antibody Positive hepatitis B surface antigen Any exposure investigational drug device within 30 day prior screen IVIG treatment within 60 day screen Plasmapheresis immunoadsorption within 60 day screen Subject current medical condition , opinion Investigator , may compromise safety compliance , preclude successful conduct study , interfere interpretation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>